Isabl’s rapid whole-genome analysis opens the playbook for cancer treatment

Every cancer is unique because every person is unique, and one of the most important weapons in any cancer battle is information. Isabl offers that in abundance through rapid sequencing of cancer cells’ entire genomes, potentially showing which therapies will and won’t be effective within days. The company has received a breakthrough designation from the FDA and raised $3 million to bring its approach to market.
The last ten years have brought numerous medical advances due to the commoditization of genomic processes from sequencing to analysis, and cancer treatment is no exception.

リンク元